pyrazines has been researched along with ixazomib in 9 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 9 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bannerman, B; Berger, A; Blank, J; Bolen, J; Bruzzese, F; Cao, Y; Dick, L; Fitzgerald, M; Fleming, P; Garcia, K; Hales, P; Kupperman, E; Lee, EC; Liu, J; Manfredi, M; Rolfe, M; Tsu, C; Yang, Y; Yu, J; Yu, L | 1 |
Anderson, KC; Chauhan, D; Kuhn, D; Orlowski, R; Raje, N; Richardson, P; Tian, Z; Zhou, B | 1 |
Bannerman, B; Bano, K; Berger, AJ; Bolen, JB; Bradley, DP; Carsillo, M; Donelan, J; Fitzgerald, M; Hales, P; Janz, S; Kupperman, E; Lee, EC; Li, P; Li, Z; Liu, R; Manfredi, M; Neppalli, VT; Pickard, M; Silva, MD; Subakan, O; Tayber, O; Terkelsen, J; Van Ness, B | 1 |
Appel, A | 1 |
Abe, M; Fujii, S | 1 |
Hu, Y; Wu, P; Zhang, J | 1 |
Cavallo, F; Genadieva-Stavric, S; Palumbo, A | 1 |
Yagi, H | 1 |
Mitsiades, CS | 1 |
3 review(s) available for pyrazines and ixazomib
Article | Year |
---|---|
Clinical and marketed proteasome inhibitors for cancer treatment.
Topics: Boron Compounds; Boronic Acids; Bortezomib; Glycine; Humans; Lactones; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyrroles; Structure-Activity Relationship; Threonine | 2013 |
New approaches to management of multiple myeloma.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Depsipeptides; Frail Elderly; Glycine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Oligopeptides; Phosphorylcholine; Proteasome Inhibitors; Pyrazines; Quality of Life; Recurrence; Thalidomide; Treatment Outcome | 2014 |
[Proteasome inhibitor].
Topics: Boron Compounds; Boronic Acids; Bortezomib; Glycine; Humans; Molecular Targeted Therapy; Neoplasms; Proteasome Inhibitors; Pyrazines; Ubiquitin | 2014 |
6 other study(ies) available for pyrazines and ixazomib
Article | Year |
---|---|
Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer.
Topics: Animals; Boron Compounds; Boronic Acids; Bortezomib; Cysteine Proteinase Inhibitors; Drug Screening Assays, Antitumor; Female; Glycine; HCT116 Cells; HT29 Cells; Humans; Lymphoma; Mice; Mice, SCID; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays | 2010 |
In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Biological Availability; Blotting, Western; Boron Compounds; Boronic Acids; Bortezomib; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dexamethasone; Drug Synergism; Enzyme Activation; Glycine; Humans; Lenalidomide; Mice; Mice, SCID; Multiple Myeloma; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thalidomide; Xenograft Model Antitumor Assays | 2011 |
Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.
Topics: Animals; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Glycine; Humans; Lymphoma, B-Cell; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Neoplasms, Plasma Cell; Osteolysis; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Xenograft Model Antitumor Assays | 2011 |
Drugs: More shots on target.
Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Clinical Trials as Topic; Drug Resistance, Neoplasm; Glycine; Humans; Immunologic Factors; Lenalidomide; Multiple Myeloma; Oligopeptides; Protease Inhibitors; Pyrazines; Survival Rate; Thalidomide; Threonine | 2011 |
[Molecular targeting agents for multiple myeloma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Glycine; Histone Deacetylases; Humans; Immunologic Factors; Lactones; Lenalidomide; Molecular Targeted Therapy; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Pyrazines; Pyrroles; Thalidomide | 2012 |
Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.
Topics: Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Cell Line, Tumor; Clinical Trials as Topic; Glycine; Hematologic Neoplasms; Humans; Neoplasms; Oligopeptides; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Signal Transduction; Ubiquitin | 2015 |